Northwest Biotherapeutics (NWBO) Shares are Up 39.12%

Northwest Biotherapeutics (NWBO) : Traders are bullish on Northwest Biotherapeutics (NWBO) as it has outperformed the S&P 500 by a wide margin of 16.61% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 38.38%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 39.12% in the last 1 week, and is up 14.25% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 26.04% and the 50-Day Moving Average is 11.01%.The 200 Day SMA reached 68.62% Northwest Biotherapeutics, Inc. has dropped 23.23% during the last 3-month period . Year-to-Date the stock performance stands at -85.22%.


For the current week, the company shares have a recommendation consensus of Buy. Northwest Biotherapeutics (NASDAQ:NWBO): The stock opened at $0.42 and touched an intraday high of $0.4995 on Friday. During the day, the stock corrected to an intraday low of $0.391, however, the bulls stepped in and pushed the price higher to close in the green at $0.473 with a gain of 12.59% for the day. The total traded volume for the day was 4,312,446. The stock had closed at $0.473 in the previous trading session.

Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing immunotherapy products to treat cancer. The Companys platform technology, DCVax, uses activated dendritic cells to mobilize a patients own immune system, including T cells, B cells and antibodies and natural killer cells, among others to attack cancer cells. DCVax is designed to target a set of biomarkers on the patients tumor. DCVax product lines are made from the patients own dendritic cells, which are freshly isolated, and matured and activated. The Companys DCVax product lines include DCVax-L, DCVax-Direct and DCVax-Prostate. DCVax-L is made with cancer antigens from tumor lysate. DCVax-Direct incorporates a set of tumor antigens in situ. DCVax-Prostate product line is developed based on the antigen, PSMA (Prostate Specific Membrane Antigen), which is found on all late stage prostate cancers.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *